Shionogi keeps arm's length finger in HIV pie as ViiV acquires dolutegravir rights
This article was originally published in Scrip
Executive Summary
As its lead development molecule nears a first regulatory filing by year-end on the back of a positive dataset, the Shionogi-ViiV Healthcare HIV joint venture has solidified commercial plans that involve both the Japanese partner taking a step back and the integrase inhibitor JV itself being dissolved.
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.